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Background: Closed-loop insulin delivery is an emerging treatment for type 1
diabetes (T1D) evaluated clinically and using computer simulations during pre-clinical
testing. Efforts to make closed-loop systems available to people with type 2 diabetes
(T2D) calls for the development of a new type of simulators to accommodate differences
between T1D and T2D. Presented here is the development of a model of posthepatic
endogenous insulin concentration, a component omitted in T1D simulators but key for
simulating T2D physiology.
Methods: We evaluated six competing models to describe the time course of
endogenous insulin concentration as a function of the plasma glucose concentration
and time. The models were fitted to data collected in insulin-naive subjects with T2D
who underwent two 24-h visits and were treated, in a random order, by either
closed-loop insulin delivery or glucose-lowering oral agents. The model parameters
were estimated using a Bayesian approach, as implemented in the WinBUGS software.
Model selection criteria were used to identify the best model describing our clinical data.
Results: The selected model successfully described endogenous insulin
concentration over 24 h in both study periods and provided plausible parameter
estimates. Model-derived results were in concordance with a clinical finding
which revealed increased posthepatic endogenous insulin concentration during
the control study period (P < 0.05). The modelling results indicated that the excess
amount of insulin can be attributed to the glucose-independent effect as the
glucose-dependent effect was similar between visits (P > 0.05).
Conclusions: A model to describe endogenous insulin concentration in T2D including
components of posthepatic glucose-dependent and glucose-independent insulin
secretion was identified and validated. The model is suitable to be incorporated in
a simulation environment for evaluating closed-loop insulin delivery in T2D.
Keywords: Posthepatic endogenous insulin concentration, Closed-loop insulin
delivery, Simulation, Modelling, Insulin secretion, Type 2 diabetesBackground
The ‘artificial pancreas’, or closed-loop insulin delivery system, is a state-of-the-art
medical device designed to improve glycaemic control by automatically titrating insulin
delivery according to real-time continuous glucose sensor values [1]. Over the past
decade a large number of clinical studies have been undertaken to assess the safety© 2015 Ruan et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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nant women [4] with type 1 diabetes (T1D). Home trials have also shown favourable re-
sults of improved glucose control in participants with T1D utilizing closed-loop during
their normal daily life [5,6]. Further clinical investigations are in the pipeline aiming to
extend the application of closed-loop to benefit a larger population with type 2 diabetes
(T2D). Recently reported clinical study tested the feasibility and safety of closed-loop in
insulin-naïve T2D subjects [7] and showed promising results.
Clinical studies in humans are costly and time consuming. A virtual testing environ-
ment where a population of synthetic subjects with diabetes is tested in a virtual com-
puter space provides a plausible alternative to assess the closed-loop performance in a
more time-saving and cost-effective way. It also allows to test scenarios which might
not be ethical to perform in real human subjects, so that it gives insight into the limit
and a better design of the underlying control algorithm [8,9]. The simulator usually in-
corporates, as a key component, a glucoregulatory mathematical model and a number
of virtual subjects represented by individualized model parameters. However, most of
the present simulation models have been developed for T1D [9]. With the growing
interest of bringing closed-loop to people with T2D [10], a simulation environment
with a glucoregulatory model reflecting glucose-insulin interactions in T2D is desired.
In order to create a virtual population of subjects with T2D, a simulation model devel-
oped for T1D needs to be supplemented with a model of endogenous insulin secretion
and ensuing endogenous insulin concentration.
With this objective in mind, we aimed to develop a posthepatic insulin concentration
model and evaluate it with insulin/glucose data collected during a clinical trial in T2D
subjects [7]. Six competing models were proposed and the best model was selected on
the basis of our model selection criteria. The model of choice assumes a linear relation-
ship between glucose-dependent posthepatic insulin secretion and plasma glucose, and
incorporates two two-segment linear functions representing glucose-independent post-
hepatic insulin secretion after breakfast and lunch, respectively. The model successfully
described endogenous insulin concentration data in 11 subjects with T2D, who under-
went two 24-hour visits and were treated by either closed-loop insulin delivery or
glucose-lowering oral agents.Methods
Subjects and experimental design
We utilised data obtained from a clinical study involving 11 subjects [6 male, age 59.7
(12.1) years, BMI 30.1 (3.9) kg/m2, diabetes duration 8.0 (6.2) years and HbA1c 8.3
(0.8)%, mean (SD)] with non-insulin treated T2D, who underwent two 24-hour visits
(from 9:00 a.m. on Day 1 until 9:00 a.m. on Day 2), four to six weeks apart, in a random
order, treated by either closed-loop insulin delivery or glucose-lowering oral agents [7].
The study was approved by the Cambridge Research Ethics Committee and subjects
signed informed consent prior to the commencement of the study.
During closed-loop visits, subjects’ routine diabetes therapy was discontinued the
night before and replaced with model predictive control algorithm-driven subcutaneous
insulin pump delivery of rapid-acting insulin analogue lispro (Eli Lilly, Indianapolis, IN),
based on real-time continuous glucose monitoring. Meals were unannounced to the
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betes regimen was continued (metformin 92%, sulfonylureas 58%, DPP-4 inhibitors 33%).
On both visits, subjects consumed matched 50-80 g carbohydrate meals at 0, 240 and
540 min relative to 9:00 a.m. on Day 1, and optional 15 g carbohydrate snacks. Blood sam-
ples were collected, every 15 minutes for measuring glucose concentration, and at the
following time points: 0,15, 30, 45, 60, 90, 120, 150, 180, 210, 240, 255, 270, 285, 300, 330,
360, 390, 420, 450, 480, 510, 540, 555, 570, 585, 600, 630, 660, 690, 720, 750, 780, 810,
840, 870, 900, 960, 1020, 1080, 1140, 1200, 1260, 1320, 1380 and 1440 min, for measuring
endogenous plasma insulin concentration.Insulin and glucose measurement
Samples were centrifuged immediately with plasma kept on ice and stored at – 80°C
until assayed. Endogenous plasma insulin was measured by AutoDELFIA immunoassay
(Perkin Elmer Life Sciences, Wallac Oy, Turku, Finland; inter-assay CV 3.1% at 29
pmol/l, 2.1% at 79.4 pmol/l, 1.9% at 277 pmol/l, 2.0% at 705 pmol/l) which has zero
cross reactivity with insulin lispro administered during the closed-loop visits. Plasma
glucose was measured by YSI2300STAT Plus Analyser (YSI, Fleet, Hampshire UK).Model description
We developed six models of increasing complexity to describe endogenous plasma in-
sulin concentration [IENDO(t)] as a function of plasma glucose concentration [G(t)] and
time. A schematic representation of the six competing models is shown in Figure 1. We
incorporate the glucose-dependent model components (in Model 1 to 6) and additionally
the glucose-independent components (in Model 4 to 6). Models’ mathematical formula-
tions are provided in Additional file 1.
Model 1, the base model, assumes a linear relationship between the rate of posthepa-
tic insulin secretion Is(t) (mU/min) and measured plasma glucose concentration G(t)
(mM). This assumption originates from previous studies which demonstrated linearity
between the prehepatic insulin/C-peptide secretion and the plasma glucose concentra-
tion [11,12]. IENDO(t) (mU/l), the measured endogenous plasma insulin concentration
and model output, is assumed proportional to Is(t), through the inverse of the product
of insulin metabolic clearance rate MCRI (l/kg/min) and subject’s body weight W (kg).
This assumption is based on the relatively short plasma insulin half-life (~5 min) com-
pared to the sampling frequency in our study (15 to 60 min), allowing us to assume an
instantaneous equilibration between posthepatic insulin appearance in plasma and
plasma insulin [13]. The individual parameter values of MCRI are taken from our previ-
ous study [13]. In Eq. (1), Additional file 1, Gb (mM) is the fasting plasma glucose con-
centration; MI (mU/min/mM) is the posthepatic glucose sensitivity, representing the
effect of unit change in blood glucose concentration on posthepatic insulin secretion
and M0 (mU/min/mM) is the basal glucose sensitivity, representing effect of fasting
plasma glucose on posthepatic insulin secretion.
Model 2 has the same structure as Model 1 but adopts different MI and M0 values
during postprandial and fasting periods. In this model, the 24-hour study period is
divided into four time intervals, post-breakfast (4 h), post-lunch (5 h), post-dinner (7 h)
and overnight (fasting time, 8 h), with each time interval holding a different MI and M0
Figure 1 Schematic representation of the six competing models. The models are represented with the
(A) glucose-dependent and (B) glucose-independent parameters.
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rameters with subscripts b, l, d and f, representing the four time intervals. In the same
fashion, M0 adopts four subscripts, with M0,b being the estimated parameter from
which values of M0,l, M0,d and M0,f can be derived. This derivation is to satisfy the
assumption that the time course of G(t), Is(t) in a two-dimensional space is continuous
throughout the study period. tl, td, tf and tend are at 240, 540, 960 and 1440 min,
respectively; these values are assigned according to meal times.
Model 3 expands on Model 2 by further dividing the post-breakfast period into two
sub-periods with an additional breakpoint at tb = 90 min, highlighting the difference of
the first meal of the day after an overnight fast.
The weighted residuals of Model 3 (Figure 2) show postprandial underestimation of
plasma insulin level indicating that underlying factors other than glucose stimulation
influence the posthepatic insulin secretion. Thus, in Model 4, a two-segment piecewise
linear function representing additional posthepatic insulin secretion after breakfast Iadd,
b(t) is added. This additional flux assumes value 0 at t = 0, peaks at t=tpeak,b = 30 min
and falls gradually to 0 at t=tend. The peak value Ipeak,b (mU/min) is estimated.
The weighted residuals of Model 4 (Figure 2) shows improved post-breakfast model
fit but underestimation of insulin concentration still exist after lunch and dinner time.
Therefore, in Model 5, another two-segment piece-wise linear function Iadd,l (t) is
added after lunch time. Similar to the post-breakfast flux in Model 3, the post-lunch
flux assumes value 0 at t = tl = 240 min, peaks at t=tpeak,l =270 min and drops to 0 at
t=tend. The peak value Ipeak,l (mU/min) is estimated.
Finally, in addition to Model 5, Model 6 assumes a derivative action of G(t)on the
posthepatic insulin secretion as a number of studies claimed derivative action of glu-
cose concentration on prehepatic insulin secretion [11]. Id(t) (mU/min) is the posthe-
patic insulin secretion triggered by the positive rate of change of glucose concentration;
Md (mU/mM) is the dynamic glucose responsivity representing the ability of glucose
rate of change to stimulate posthepatic insulin secretion (Eq. (6), Additional file 1).Model selection and parameter estimation
Parameters of the six competing models were identified on clinical data obtained from
the closed loop periods and the results were used in model selection criteria. The pa-
rameters of the model of choice were subsequently identified on data obtained from
the control period.
In the first instance, all six models were numerically identified using glucose/insulin
data obtained from the closed-loop period, using a Bayesian approach. WinBUGS
(Bayesian inference Using Gibbs Sampling for Windows) software version 1.4 (MRC
Biostatistics Unit, Cambridge, UK) [14] was used for model identification. The meas-
urement error in IENDO(t) was assumed to be uncorrelated, normally distributed with
zero mean, and with a coefficient of variation at 6%. The plasma glucose concentration
represented by G(t), being the model input, was assumed error free.
The initial model identification results were used to select the best model on the
basis of the following criteria: (i) the deviance information criterion (DIC) which is a
measurement of model parsimony, taking into account the goodness of fit and the
model complexity [15], (ii) the weighted residual profiles documenting overall model
Figure 2 Median weighted residuals obtained with the six competing models. Weighted residuals are
difference between model predictions and data divided by the standard deviation. The error bars represent
the interquartile range (n = 11). Data collected from the closed-loop experiments were used.
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indicate increased model complexity leading to over-fitting. The model of choice was
then identified on data obtained from the eleven control periods.
The individual parameter sets of the best model were identified using the Bayes Theorem:
pðθjyÞ ¼ p θð ÞpðyjθÞZ
p θð Þp yjθð Þdθ
∝p θð Þp y θÞjð
where y is the dataset of the posthepatic endogenous insulin concentration measurements,
θ represents the unknown parameters MI,b1, MI,b2, MI,l, MI,d, MI,f, M0,b1, M0,b2, M0,l, M0,d,
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their a priori distributions p(θ)which are updated by the likelihood p(y|θ), yielding parame-
ters’ a posteriori distributions p(θ|y). The integral ∫p(θ)p(y|θ)dθ acts as a scale factor.
In the present study, vague prior information was assigned to each parameter. For
each study period, it took WinBUGS 550 seconds to run 100,000 iterations and pro-
duce posterior parameter distributions. A standard 64-bit desktop PC (OPTIPLEXTM
7010, DELLTM Computers Ltd) was used. The first 10,000 iterations were discarded as
burn-ins to allow the initial stabilization of the Markov chain [16].Statistical analysis
Results are shown as median (interquartile range), if not differently indicated. The
Wilcoxon signed-rank test was used to assess the between-sample difference due to
the non-normal data. SPSS software version 21 [17] was used to carry out the statistical
analysis where P values less than 0.05 were considered statistically significant.Results
Endogenous plasma insulin concentration
Table 1 compares the area-under-curve (AUCins) of measured endogenous plasma insulin
concentration between visits. A significant increase in the control period AUCins can be
observed during the three postprandial time intervals as well as during the fasting condi-
tions (P < 0.05) suggesting an increase in posthepatic insulin secretion throughout the
control period.Model selection
Figure 2 illustrates weighted residual profiles obtained with the six competing models.
Model 5 and Model 6 result in comparable profiles and provide the best fit to the data.
Table 2 shows results of the DIC analysis. As expected, the deviance D decreased and
the ‘effective number of parameters’ pD increased with the increasing model complex-
ity. Model 6 outperforms the other five models in terms of the lowest DIC value. How-
ever, following model identification, we noted that the parameter Md, exclusive to
Model 6, was estimated to be zero in 9 out of the 11 tested data sets. Model 6 was
therefore rejected and Model 5 became the model of choice as it adequately described
the data and held the second lowest, after Model 6, DIC value.Table 1 The area under the curve (AUCins) of the model-derived endogenous plasma
insulin concentration
Closed-loop (n = 11) Control (n = 11) P-value
AUCins (10
3 · min · mU/l)
Post-breakfast 6.4 (3.6,7.9) 7.4 (4.9,10.4) 0.006
Post-lunch 7.4 (4.0,10.0) 10.9 (8.2,13.9) 0.026
Post-dinner 6.7 (4.3,10.5) 7.8 (6.9,15.9) 0.048
Fasting 3.1 (2.1,3.8) 4.6 (3.2,7.7) 0.003
Table 2 Results of DIC analysis for the six competing models
Model D D^ pD DIC d
1 9003 8982 21 9024 5597
2 6435 6409 26 6461 3034
3 4482 4435 47 4529 1102
4 4079 4024 55 4134 707
5 3394 3335 59 3453 26
6 3357 3287 70 3427 0
D ¼ posterior mean of -2log(likelihood); D^ ¼ 2log(likelihood) at posterior mean of stochastic nodes; pD ¼ D−D^ , defines
“effective number of parameters”; DIC ¼ D þ pD , is deviance information criteria. d is the difference between the present
model’s DIC and the lowest DIC.
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Figure 3 shows weighted residual profiles for both closed-loop and control periods
documenting overall plausible model fit to data using Model 5. Individual model fits
are provided in Additional file 1. An example fit shown in Figure 4 confirmsFigure 3 Weighted residuals during (top panel A) closed-loop and (bottom panel B) control period
using Model 5.
Figure 4 Sample model fit obtained with subject 7. The model fit (with Model 5) to endogenous plasma
insulin concentration (upper panel) with plasma glucose excursion (lower panel) during closed-loop (left panel)
and control period (right panel); solid line represents model prediction, dashed line 95% intervals, the dotted
vertical lines indicate meal time and full circles dots represent measurements).
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between plasma glucose and endogenous plasma insulin levels.
Table 3 reports estimates of model parameters MI, M0 and Ipeak. Median estimates of
MI,f are zero on both occasions. When comparing the parameter estimates between
visits, there is no significant difference in eitherMI orM0 (P > 0.05) – the ability of glucose
concentration to stimulate posthepatic insulin secretion is similar between treatments.Table 3 Parameter estimates for Model 5
Model parameters Closed-loop (n = 11) Control (n = 11) P-value
MI,b1 (mU/min/mM) 2.6 (1.6,3.2) 4.3 (2.0,5.3) 0.11
MI,b2 (mU/min/mM) 1.0 (−0.2,2.7) 1.6 (0.1,4.7) 0.59
MI,l (mU/min/mM) 5.0 (1.8,6.6) 2.7 (0.0,8.5) 0.48
MI,d (mU/min/mM) 3.0 (2.5,4.8) 4.8 (0.2,8.2) 0.25
MI,f (mU/min/mM) 0.0 (0.0,1.8) 0.0 (0.0,6.0) 0.59
M0,b1 (mU/min/mM) 1.1 (0.9,1.7) 1.3 (0.3,1.5) 0.48
M0,b2 (mU/min/mM)
* 1.9 (1.6,2.2) 1.7 (1.0,2.7) 0.72
M0,l (mU/min/mM)
* 1.8 (1.1,2.8) 1.8 (1.3,2.7) 0.66
M0,d (mU/min/mM)
* 1.6 (0.9,2.0) 1.6 (1.0,2.3) 0.59
M0,f (mU/min/mM)
* 0.7 (0.4,1.1) 0.8 (0.6,1.5) 0.48
Ipeak,b (mU/min) 7.8 (0.0,14.0) 17.8 (0.0,21.1) 0.27
Ipeak,l (mU/min) 0.0 (0.0,13.9) 13.2 (0.0,30.5) 0.02
MCRI (l/kg/min)
** 0.013 (0.005) as Closed-loop NA
*Derived parameter.
**Assumed parameter, mean (SD).
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the closed-loop visit (P < 0.05).
Table 4 compares model-derived AUCins and its glucose-dependent and glucose-
independent components between visits. The AUCins is significantly larger during the
control period (P < 0.05), with the excess amount only attributable to the glucose-
independent component (P < 0.05). The glucose-dependent AUCins show no discordance
between visits (P > 0.05).Discussion
We present a model describing the time course of 24-h endogenous plasma insulin
concentration in people with T2D. The model was identified on insulin/glucose data
obtained from 11 insulin-naïve T2D subjects who underwent two 24-hour visits treated
by either closed-loop insulin delivery or glucose-lowering oral agents. Both clinical and
model-derived results suggested an increase in the amount of posthepatic endogenous
insulin secretion during the control period, namely the oral agents-treated period. The
modelling results further suggested that the surplus insulin secretion was glucose-
independent. We consider the model suitable to be incorporated in a simulation environ-
ment for testing closed-loop inulin delivery performance in T2D.
In the model development process, six competing models of increasing complexity
have been evaluated. All models adopted the following assumptions: a linear relation-
ship exists between plasma glucose concentration and posthepatic insulin secretion
rate; MCRI is identical between study visits; the equilibration is instantaneous between
posthepatic insulin appearance in plasma and plasma insulin, reflecting a short plasma
insulin half-life relative to the frequency of plasma insulin measurements. The latter
assumption was adopted in our previous study during which individual MCRI values
were estimated [13].
In order to select the model best representing our data sets, three criteria were
adopted. Based on the DIC criterion (Table 1), Model 6 would have been chosen as the
most parsimonious. However, the parameter estimates of Md converged to zero in 82%
of the cases implying that Model 6 collapsed into Model 5 and that the contribution of
the derivative action of glucose concentration on posthepatic insulin secretion was
overall negligible. Therefore, Model 6 was rejected and Model 5 became our model of
choice. In terms of model parameter estimation, we found that, unlike MI,b, MI,l and
MI,d, which represent posthepatic glucose sensitivities after breakfast, lunch and dinner
and which had non-zero estimates, the median estimates of MI,f were zero for both
visits. This may suggest that the linear relationship between plasma glucose and plasma
insulin may be less pronounced during the fasting period, probably due to the lessTable 4 Comparison of model derived glucose-dependent, glucose–independent plasma
insulin concentration and the total AUCins
Closed-loop (n = 11) Control (n = 11) P-value
AUCins (10
3 · min · mU/l)
Glucose-dependent 14.8 (12.1,21.0) 15.1 (11.3,19.5) 0.930
Glucose-independent 9.8 (3.7,14.9) 21.3 (8.5,24.5) 0.004
Total 23.5 (15.3,30.0) 35.8 (24.7,49.7) 0.006
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cated model structure may be required to describe the ‘plasma glucose-endogenous
plasma insulin’ relationship overnight.
Additional file 1 shows plots of measured plasma glucose concentration versus en-
dogenous plasma insulin concentration. Given the assumption of linearity, we should
have observed a unique linear dependency between measurements for each of the time
intervals. However, in a few subjects, namely in subjects 2, 3, 4, 6, 8 during the closed-
loop period and subjects 2, 4, 6, 8, 10 during the control period, the endogenous
plasma insulin concentration remains high or continues to increase despite a pro-
nounced drop in the plasma glucose level, especially after the first meal of the day. This
observation encouraged us to incorporate the glucose-independent insulin secretion
component.
The bioactive incretins, namely glucagon-like peptide-1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP), are hormones released from the small intestine in
response to oral meal intake, acting as enhancers to endogenous insulin secretion.
Woerle et al. demonstrated that incretins play a relatively more important role in
amplifying insulin secretion in people with T2D compared to healthy subjects [18].
We therefore hypothesize that the glucose-independent insulin secretion functions
in our model may account for, at least in part, the insulinotropic effect of incretin
hormones, and may correspond to the ‘potentiation’ of insulin secretion after meal
proposed by Mari et al. [11].
The excess amount of glucose-independent insulin secretion during the control
period revealed by the modelling process may be attributed to the effect of glucose-
lowering agents. As suggested in literature, metformin (taken by 92% of the studied
subjects during the control period) enhances GLP-1 action [19], sulfonylureas (taken by
58% of the studied subjects) stimulates endogenous insulin secretion [20] and DPP-4
inhibitors (taken by 33% of the studied subjects) improves insulin secretion and prolongs
GLP-1 action [21].
Insulin and C-peptide are co-secreted equimolarly by the pancreatic beta-cells. After
travelling through the liver, about 50% of insulin is extracted before entering the plasma
while C-peptide is not affected. The prehepatic insulin secretion profile can, therefore,
be reconstructed using a model of C-peptide kinetics [22] where the beta-cell function
can be assessed quantitatively [11,12,23]. However, the objective of this study was to
describe posthepatic insulin concentration with a relatively simple model. Thus, plasma
C-peptide concentration was not measured in the present study.
The model can be implemented in a simulation environment designed specifically for
accelerating the development of closed-loop insulin delivery systems for T2D. The
endogenous insulin secretion characteristics of the virtual subjects with T2D will be
represented by individual model parameters identified in the present study. The model
may also be used in pharmaceutical development. In a possible application, model
parameters identified using data collected before and after the ingestion of a tested
glucose-lowering agent could be compared. The comparison may help to evaluate the
efficacy of a new drug to influence, for instance, the posthepatic glucose sensitivity MI.
The model’s ability to quantitatively evaluate effects of altered glucose turnover on en-
dogenous insulin secretion, when patients’ usual glucose-lowering oral agent is replaced
with subcutaneous insulin therapy, may also be of clinical relevance [24].
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between study visits. However, no studies to date have shown that discontinuing exogenous
insulin administration or oral hypoglycaemic therapy could affect plasma insulin clearance
rate. Our previous study in subjects with T1D [25] supported this assumption by
demonstrating reproducibility of all insulin aspart pharmacokinetic parameters
including the insulin clearance rate.
In conclusion, a model describing 24-h posthepatic endogenous insulin concentration in
T2D is proposed. The model was evaluated on clinical data obtained in subjects with T2D
treated by either closed-loop insulin delivery (closed loop period) or by glucose-lowering
oral agents (control period). The clinical results showed an increased posthepatic insulin
secretion during the control period. The modelling results further suggested that this
excess is glucose-independent. The presented model is suitable for application in an in
silico simulation environment for testing closed-loop insulin delivery algorithms in T2D.
Additional file
Additional file 1: Mathematical formulation of the six competing models. Model fits to the individual data
sets. Plasma glucose concentration vs. endogenous plasma insulin concentration.
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